上皮性卵巢癌中IRSp53的表达及其临床意义

Expression and clinical significance of IRSp53 in epithelial ovarian cancer

目的探讨胰岛素受体底物p53蛋白(insulin receptor substrate p53,IRSp53)在上皮性卵巢癌(epithelial ovarian cancer,EOC)中的表达,及其与临床病理特征、预后之间的关系。方法采用免疫组化SP法和Western blot法检测不同病理类型卵巢组织中IRSp53的表达。结果 IRSp53在EOC中的阳性率为62.82%,显著高于正常卵巢(4.55%)、良性卵巢肿瘤(18.75%)及交界性卵巢肿瘤(26.67%)(P<0.05)。IRSp53在EOC中的表达与患者血清CA125水平、FIGO分期、分化程度及术后肿瘤残余直径相关(P<0.05)。IRSp53在EOC、正常卵巢、良性卵巢肿瘤和交界性卵巢肿瘤中的表达分别为1.203±0.080、0.240±0.050、0.308±0.354和0.467±0.135,差异有统计学意义(P<0.05)。IRSp53高表达的EOC患者总生存期明显低于IRSp53低表达的患者(P<0.05)。结论 IRSp53在EOC中高表达,IRSp53高表达与患者的不良预后相关,提示IRSp53可能在EOC的发生、发展中发挥重要作用。

Purpose To explore the expression of insulin receptor substrate p53 （IRSp53） in epithelial ovarian cancer （EOC） and correlation with the clinicopathologic features. Methods Immunohistoehemieal of SP and Western blot was performed to detect IRSp53 expression in ovarian tissues. Results The positive expression rate of IRSp53 in EOC （62. 82% ） was significantly higher than normal ovaries （4. 55 % ）, benign ovarian tumors （ 18.75% ） and borderline ovarian tumors （26. 67% ） （ P 〈 0. 05 ）. Furthermore, IRSp53 expression was associated with high serum CA125 level, advanced FIGO stage, poor grade and dissatisfied residual tumor size （P 〈 0. 05）. The expression of IRSp53 in EOC, normal ovaries, benign ovarian tumors and borderline ovarian tumors was 1. 203 ± 0. 080, 0. 240 ±0. 050, 0. 308 ±0. 354, and 0. 467 ±0. 135 respectively, the difference was statistically significant （P 〈0. 05 ）. The overall survival with IRSp53 overexpression was lower （ P 〈 0. 05 ）. Conclusion IRSp53 overexpression is associated with an unfavorable prognostic outcome, which suggests that IRSp53 may play a crucial role in EOC invasion and metastasis.